Inside Sun's $12bn Organon Deal: The Math, the Comps, and the Verdict

Sun Pharmaceutical Industries Ltd. has signed a definitive agreement to acquire U.S.-listed Organon & Co. for $14.00 per share in an all-cash transaction valuing the target at an enterprise value of $11.75 billion — the largest overseas acquisition in Indian pharmaceutical history and notably below the $13 billion figure leaked by the Economic Times only two days earlier. Sun beat off competing interest from Swedish private-equity firm EQT and German pain-management specialist Gruenthal; the deal is expected to close in early 2027 subject to regulatory and shareholder approvals, with financing committed by Citi, JP Morgan and MUFG. The question this note tackles is the one most readers will skip past: at the announced price, what is Sun actually paying — and how does it compare to the other large pharma deals on the table?

The Math: What Sun Is Actually Paying For Organon

Working from the definitive agreement signed by both boards on Sunday, April 26, the math is straightforward — and the multiple is materially lower than the leaked $13 billion figure had implied. Sun is paying $11.75 billion of enterprise value for an asset generating $1.9 billion of Adjusted EBITDA. That is roughly 6x.

At ~6.2x trailing EBITDA and ~1.9x revenue, Sun is paying less than half of what it would have implied at the leaked $13 billion figure. Note one nuance worth flagging: Organon recently closed a product divestiture that brought in $440 million of upfront cash. That cash flows directly to the March 31, 2026 balance, reducing assumed net debt and explaining why the headline EV came in below the leak. The headline multiple looks cheap. The question is whether it should.

How It Stacks Up: Recent India Pharma M&A Comps

Sun's ~6x sits at the very bottom of the comp set for large pharma control trades of the past three years. The five most relevant data points:

Note: EV figures for the Cipla bids are implied from the per-share offer extrapolated to 100% equity; both deals were rejected. EBITDA for unlisted/private targets is approximate, based on disclosed margins and revenue.

The Blackstone–Cipla Moment

The Cipla auction of 2023 is the most useful reference for the Organon transaction because both involve control trades for generics-heavy commercial platforms with stable but unexciting growth. The Cipla saga also tells you why Organon's board accepted at $14 a share rather than holding out for more.

Blackstone's August 2023 bid for the Hamied family's 33.47% promoter stake in Cipla was $3.8 billion, at approximately Rs 900 per share. Triggering the mandatory 26% open offer would have taken total potential outlay to ~Rs 55,926 crore (~$6.75bn). At a 100%-equity look-through, that implied an EV of roughly $8.5 billion against ~$715 million of forward EBITDA — about 12x. Critically, Blackstone's offer was essentially at the unaffected market price, with no meaningful premium. Torrent then walked in at Rs 1,200 per share — a 30%+ premium, implying ~16x EV/EBITDA. The promoter family rejected both, and the auction collapsed over valuation disagreements.

What Cipla established was a 12–16x band as the implicit floor and ceiling for a generics-led control trade in this market: a financial buyer wouldn't pay above 12x without synergy capture, and a strategic buyer needed roughly 16x to win. Sun's 6x for Organon is almost half the Blackstone floor. That is not because Sun has been aggressive on price; it is because Organon comes with $7.6 billion of net debt that Cipla never carried, a low-single-digit revenue decline that Cipla never had, and a parent-company spin-out structure that left it without natural support. The asset trades at a distressed multiple because the asset is, financially, in distress. Organon's board accepted the offer because $14 a share was meaningfully above the unaffected stock price, the deal is all-cash, and no other bidder could finance the assumption of $7.6 billion of debt at this scale.

Why the Multiple Looks Cheap (and Why It Isn't)

Three readings, all true at once:

1. Cheapest in the comp set, by a wide margin. At ~6x, Sun is paying roughly a quarter of what Mankind paid for Bharat Serums (22–23x) and Torrent paid for JB Chemicals (~25x), and half of what Blackstone offered for Cipla (12x). But BSV and JBCP are growing, ~30%-margin businesses with clean balance sheets. Organon is shrinking and carrying $7.6bn of MSD-inherited net debt. The 6x is the price of distress, not a bargain.

2. Below the leak by a meaningful gap. The Economic Times reported a $13 billion figure on Friday; the signed deal came in at $11.75 billion enterprise value. Part of the gap is Organon's $440m product divestiture closing in March 2026, which boosts cash and reduces assumed net debt. The rest is Sun's discipline: with EQT and Gruenthal not matching, Sun did not have to stretch to the leak. The market read this as a win — Sun stock rose ~7% on the announcement.

3. Synergy is now the upside, not the thesis. At 11x, every $200m of synergy was worth roughly one turn. At 6x, the math reverses: the entry multiple alone clears the hurdle, and synergy capture (Sun has guided to "significant revenue upside opportunities" alongside cost synergies) becomes the value-creation premium on top. Combined company EBITDA is expected to nearly double, with post-deal net debt/EBITDA at 2.3x and operating cash flows funding deleveraging.

Strategic Logic: Synergies and Portfolio Fit

The Organon pursuit reflects four objectives that together explain why a strategic buyer can pay what a financial buyer cannot. First, it sharpens Sun's U.S. specialty mix, accelerating the company's ongoing shift away from commodity generics toward branded and specialty products. Second, it creates commercial leverage — Sun's existing specialty salesforce, contracting relationships and U.S. regulatory infrastructure can be deployed across Organon's portfolio without proportional cost. Third, it solves for capability gaps in biosimilars, where the manufacturing, comparability and payer-contracting infrastructure is slow and expensive to build internally. Fourth, it improves resilience: with pricing pressure on small-molecule generics and geopolitical noise around supply chains, specialty franchises and biologics alternatives offer structurally stronger revenue profiles. None of these levers are available to EQT or Gruenthal at the same scale.

Conclusion: A Cheap Multiple That Only Sun Can Earn

On the screen, the deal looks like a financial sponsor's dream — ~6x EV/EBITDA on a $1.9bn-EBITDA business with cash-generative women's health franchises, available because the parent shed it with $8.6bn of debt strapped on. Yet the financial sponsors didn't win. EQT could run the model, see the discount to Mankind–BSV at 22x and Torrent–JBCP at 25x, and conclude this is the cheapest large pharma asset on the table — but Sun closed it.

The multiple is cheap precisely because the asset is hard. Refinancing $7.6bn of net debt is the easy part — every bidder can do that. The real work is stabilizing a revenue base in low-single-digit decline, integrating a U.S. specialty salesforce into an existing one, building out biosimilars commercial scale, and protecting Nexplanon's franchise economics through the next contraceptive cycle. That is operating work, not financial engineering, and it is exactly the kind of work Sun has done at scale before — through Taro, through Ranbaxy, through every U.S. generics consolidation of the last fifteen years. The combined company will operate in 150 countries, with 18 markets generating over $100 million each, combined revenue of $12.4 billion, and a position among the world's top 25 pharmaceutical companies by sales. Sun is also expected to become a top-three global player in women's health.

EQT and Gruenthal could match the cheque. Neither could match the integration playbook — and neither could match the multiple arbitrage. Sun Pharma trades at roughly 32x earnings on the Indian market; every dollar of incremental EBITDA bought at ~6x and folded into Sun gets implicitly re-rated to that listed multiple, an instant value transfer that a private buyer holding the asset on its own balance sheet simply cannot capture. The 7% Sun stock rally on Monday is the public-market endorsement of exactly that math.

That is the deeper reason this is the right deal for the right buyer at the right price. For Sun, Organon is a long-term strategic bet: a U.S. specialty platform, a biosimilars engine and a women's health franchise that compound over a decade alongside an existing global commercial machine, with combined EBITDA expected to nearly double and post-deal leverage at a manageable 2.3x. For EQT, Gruenthal or any other financial sponsor, it would have been a leveraged bet on a declining asset where the upside is bounded by what an exit buyer will pay in five years. The 6x multiple is not the price of a bargain; it is the price of an uphill battle that Sun is the only bidder in the room equipped to actually win — which is why, once the auction was over, no one else was left in the room.

Poornima Vardhan and Taponeel Mukherjee are principals at AltG Investment Research Lab. Views are personal. They can be contacted at: ideas@altgind.com

Disclaimer: Any views, comments or communication above should not be construed to be investment advice by Alternative Growth ("AltG") in any form whatsoever. AltG does not make an offer to sell or solicit to buy any securities. Multiples and EV figures are derived from the Sun Pharma–Organon joint press release of April 26, 2026, publicly disclosed company filings, press reports (Economic Times, Business Standard, Reuters, Bloomberg, BusinessWire, CNBC) and broker research; figures for unlisted targets and rejected bids are approximate. Organon financial data sourced from the company's Q4/FY2025 earnings release.